Mumbai, September 24, 2025: Fabtech Technologies has fixed the price band of ₹ 181/- to ₹ 191 /- per Equity Share of face value ₹ 10/- each for its maiden initial public offer.
The Initial Public Offering (“IPO” or “Issue”) of the Company will open on Monday, September 29, 2025, for subscription and close on Wednesday, October 1, 2025.
Investors can bid for a minimum of Equity Shares and in multiples of Equity Shares thereafter.
Equity shares outstanding as on date 3, 23, 92, 239 Equity Shares of Rs 10 each
The IPO is a fresh issue for 1,20,60,000 equity shares
The proceeds from the fresh issue to the extent of Rs 127 crore will be for funding the working capital requirements of the company, Rs 30 crore for funding inorganic growth opportunities through acquisitions and general corporate purposes.
The company is a global company headquartered in India, specializing in turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies. Its footprint spans more than 62 countries Middle East, Africa, Asia, Europe, Latin America, North America, etc. The company has presence across some of the key emerging economies like Bangladesh, Egypt, Ethiopia, India, Kenya, Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, UAE, USA and Tanzania. (Source: CRISIL Report). The company provides extensive technical expertise and infrastructure to deliver comprehensive solutions for establishing aseptic manufacturing facilities, encompassing everything from design to certification.
The company offers comprehensive start to finish services in greenfield projects, encompassing disease identification, planning, designing, engineering, procurement, quality assurance, logistics management and installation and commissioning for a wide range of customers across various geographies, particularly key emerging economies. Additionally, the company also offers some of its engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. In such projects, the feasibility study, design and engineering and other execution functions are undertaken by third party solution providers, and our scope is limited to equipment supply or any other services, required by our customers.
The company’s comprehensive solutions encompasses the entire project lifecycle of our customers and address the three key elements in pharmaceuticals, biotech and healthcare facilities, namely, bio clean air, clean water, and process. In addition to offering targeted solutions across the value chain, the company has an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids.
Its turnkey engineering solutions involve an extensive range of services, viz., comprehensive market analysis that combines geographic and demographic insights to understand the current and future competitive environment, disease profiling for aligning solutions to the specific needs of the target market, designing and detailed engineering of equipment tailored to the manufacturing process and the applicable quality standards, leveraging the best technologies to enhance the efficiency, reliability, and sustainability of the projects and execution and commissioning strategy.
Turnkey engineering solution providers play a key role in ensuring optimal use of resources through providing comprehensive and customized solutions as per individual projects need. The company as an integrated turnkey engineering solution provider manages every aspect of the project from conception to completion, to ensure seamless and streamlined integration between various stages of the project, thereby increasing the chances of successful implementation. Turnkey engineering solution providers have experienced teams that possesses extensive knowledge of various domains, which makes them more adept at handling complex challenges effectively. (Source: CRISIL Report)
Thus, its service portfolio of consolidating robust pharmaceutical and healthcare capabilities has offered targeted support for building infrastructure in growing economies for addressing respiratory, blood renal and oncology disorders.
Its comprehensive bio clean air, clean water and process offerings, and expertise spans across executing diverse array of projects and solutions, including but not limited to, granulation solutions, isolator containment systems, injectable projects, encapsulation solutions, cleanroom infrastructure, cleanroom systems, cleanroom equipment, Heating, Ventilation, and Air Conditioning systems (“HVAC”), mechanical, electrical and plumbing
and packaging lines. Additionally, the company’s expertise in offering turnkey engineering solutions allows it to execute green field as well as brown field turnkey projects. And given the company’s experience and nuanced execution capabilities, along with offering turnkey engineering solutions, its standalone services are customizable as per the requirement of its customers, And the company caters to specific areas of the value chain, such as, equipment procurement, equipment supply, installation and commissioning, etc.
The company is a part of Fabtech Group which was established in 1995 and has over 29 years of operating history in executing pharmaceutical turnkey projects.
The company has completed 51 projects across Saudi Arabia, Egypt, Algeria, Bangladesh, Ethiopia, Sri Lanka and UAE, as on date of filing RHP. And as on July 31, 2025, the company has an order book aggregating to ₹ 904.4.
The company’s revenue from operations was Rs 326.66 crore during FY25 vis-à-vis Rs 193.79 crore during FY23.
Its net profit was Rs 46.45 crore during FY25 vis-à-vis Rs 21.73 crore during FY23.
Unistone Capital Private Limited is the book-running lead manager; and Bigshare Services Private Limited is the registrar of the offer.
The Offer is being made through the book-building process, wherein not more than 50% of the net offer is allocated to qualified institutional buyers, and not more than 15% and 35% of the net offer is assigned to non-institutional bidders and retail individual bidders respectively.
No comments:
Post a Comment